Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Randomized Study of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome

This study has been completed.
University of Virginia
Information provided by:
National Center for Research Resources (NCRR) Identifier:
First received: April 6, 2000
Last updated: June 23, 2005
Last verified: December 2003


I. Determine whether reduction of serum insulin levels by metformin increases ovulatory response to clomiphene citrate in women with polycystic ovary syndrome.

Condition Intervention
Polycystic Ovary Syndrome
Drug: clomiphene citrate
Drug: metformin

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by National Center for Research Resources (NCRR):

Estimated Enrollment: 99
Study Start Date: January 2000
Detailed Description:

PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study. Patients are randomized to one of two treatment arms.

Patients receive oral metformin or oral placebo three times daily for 7 weeks. Patients remaining anovulatory by day 49 receive metformin or placebo plus escalating doses of oral clomiphene citrate daily for 5 consecutive days, beginning on days 50, 80, and 110. Following ovulation, treatment with clomiphene citrate and metformin or placebo continues until 6 ovulatory cycles occur, pregnancy occurs, or anovulation persists. Patients receiving the placebo arm who have not ovulated on the highest dose of clomiphene citrate may be crossed over to receive metformin after a 6 week washout.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No


--Disease Characteristics--

Patients with chronic anovulation due to polycystic ovary syndrome (PCOS) who have failed clomiphene citrate

Must have oligoovulation and hyperandrogenemia

--Prior/Concurrent Therapy--

Endocrine therapy: At least 2 months since prior clomiphene citrate


  • At least 2 months since prior standard therapy (including over the counter drugs)
  • At least 2 months since prior investigational drugs
  • Prior multi/prenatal vitamins allowed

--Patient Characteristics--

Hematopoietic: Hematocrit greater than 38%


  • Liver function normal
  • No clinically significant hepatic disease


  • No clinically significant renal disease
  • Creatinine less than 1.4 mg/dL
  • No proteinuria

Cardiovascular: No clinically significant cardiac disease

Pulmonary: No clinically significant pulmonary disease


  • Thyroid function normal
  • Prolactin normal
  • Estradiol normal
  • Fasting 17 alpha-hydroxy progesterone less than 200 ng/dL OR No late onset adrenal hyperplasia 21 alpha-hydroxylase deficiency


  • Not pregnant
  • Negative pregnancy test
  • Male partner must have a normal semen analysis by WHO criteria
  • Must be in acceptable health by interview, medical history, physical exam, and laboratory tests
  • No diabetes mellitus
  • No clinically significant neurologic, psychiatric, infectious, neoplastic, or metabolic disease
  • No clinically significant malignant disease except nonmelanomatous skin cancer
  • At least 1 year since any prior drug abuse or alcoholism
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00005104

United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294-3300
United States, Louisiana
Louisiana State University School of Medicine
Shreveport, Louisiana, United States, 71130-3932
United States, Missouri
Washington University - St. Louis
St. Louis, Missouri, United States, 63110
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
Medical College of Virginia School of Medicine
Richmond, Virginia, United States, 23298-0230
University Alma Mater
Bologna, Italy, 40100
Sponsors and Collaborators
National Center for Research Resources (NCRR)
University of Virginia
Study Chair: William S. Evans University of Virginia
  More Information Identifier: NCT00005104     History of Changes
Other Study ID Numbers: 199/14915  UVA-HIC-7538  UVA-WSE026 
Study First Received: April 6, 2000
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Keywords provided by National Center for Research Resources (NCRR):
endocrine disorders
polycystic ovarian syndrome
rare disease

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Pathologic Processes
Ovarian Cysts
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Citric Acid
Hypoglycemic Agents
Physiological Effects of Drugs
Calcium Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on October 21, 2016